开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

休市中 11-06 16:08:50

1.380

+0.065

+4.94%

最高1.410	最低1.265	成交量112.05万
今开1.300	昨收1.315	日振幅11.03%
总市值6.89亿	流通市值6.89亿	总股本4.99亿
成交额151.51万	换手率0.22%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.38,"timestamp":1793952530866,"preClose":1.315,"halted":0,"volume":1120500,"delay":0,"changeRate":0.04942965779467677,"floatShares":499000000,"shares":499000000,"eps":-0.523086098586689,"marketStatus":"休市中","change":0.065,"latestTime":"11-06 16:08:50","open":1.3,"high":1.41,"low":1.265,"amount":1515085,"amplitude":0.110266,"askPrice":1.4,"askSize":165000,"bidPrice":1.38,"bidSize":237500,"shortable":0,"etf":0,"ttmEps":-0.472373649911374,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":7,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.315,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":1.228753152906199,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2681108378","title":"欧康医药新提交“BergCitPOL”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2681108378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681108378?lang=zh_cn&edition=full","pubTime":"2026-11-07 21:55","pubTimestamp":1794059739,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日成都欧康医药股份有限公司新提交“BergCitPOL”商标注册申请。商标申请详情如下：今年以来成都欧康医药股份有限公司新申请注册商标14件，截止目前公司共持有注册商标11件，另有17件商标尚在注册申请中。结合公司2026年中报财务数据，今年上半年公司在研发方面投入了531.9万元，同比增13.86%。通过天眼查大数据分析，成都欧康医药股份有限公司共对外投资了2家企业，参与招投标项目14次；财产线索方面有商标信息42条，专利信息59条，著作权信息5条；此外企业还拥有行政许可264个。数据来源：企查查以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110700018876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681689883","title":"欧康医药：11月5日董事伍丽、赵仁荣减持股份合计37万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681689883","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681689883?lang=zh_cn&edition=full","pubTime":"2026-11-06 23:13","pubTimestamp":1793978008,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月6日市场公开信息、上市公司公告及交易所披露数据整理，欧康医药最新董监高及相关人员股份变动情况：2026年11月5日公司董事,副总裁伍丽、董事赵仁荣共减持公司股份37.0万股，占公司总股本为0.3682%。欧康医药近半年内的董监高及核心技术人员增减持详情如下：欧康医药的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出35.28万，融资余额减少；融券净流入0.0，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600037591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159938","BK1515","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681862580","title":"礼邦医药-B(09637.HK)11月6日斥资3604港元回购200股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681862580","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681862580?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:01","pubTimestamp":1793973706,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1574","BK1515","BK1161","BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681851487","title":"福瑞达：坚持以化妆品、医药为主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2681851487","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681851487?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:37","pubTimestamp":1793957841,"startTime":"0","endTime":"0","summary":"证券之星消息，福瑞达(600223)11月06日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，同样是省内大消费类企业，青岛食品几乎只靠一个大单品，又在严重依赖省内市场的情况下愣是能保持业绩稳定，建议公司学习一下青岛食品，学习好的经验，不玩虚的真抓实干，实打实的把利润做上去。福瑞达回复：尊敬的投资者，您好，感谢您的宝贵建议！公司坚持以化妆品、医药为主业，持续夯实经营基本面，对标行业优秀企业优化经营管理，聚焦提升盈利水平，力争以稳健经营成果回报股东。再次感谢您对公司的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600029079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","BK0273","BK1574","BK0229","600223","09939","BK0188","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681776859","title":"11月6日键凯科技跌7.03%，圆信永丰医药健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681776859","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681776859?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:22","pubTimestamp":1793956968,"startTime":"0","endTime":"0","summary":"证券之星消息，11月6日键凯科技跌7.03%，收盘报75.37元，换手率6.23%，成交量3.78万手，成交额2.89亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为圆信永丰基金的圆信永丰医药健康A。圆信永丰医药健康A目前规模为2.82亿元，最新净值1.9213，较上一交易日上涨3.56%，近一年下跌2.59%。圆信永丰医药健康A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600028868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["150219","688356","BK1515","159938","BK1574","BK0229","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681100832","title":"生物制品概念盘中走弱，2026Q3创新药在医药板块内持仓占比降至43%|异动情报","url":"https://stock-news.laohu8.com/highlight/detail?id=2681100832","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681100832?lang=zh_cn&edition=full","pubTime":"2026-11-06 14:50","pubTimestamp":1793947859,"startTime":"0","endTime":"0","summary":"11月6日，生物制品盘中下跌3.04%，相关成分股中，近岸蛋白（688137）下跌12.18%，百普赛斯（301080）下跌11.03%，义翘神州（301047）下跌8.70%，诺唯赞（688105）下跌7.49%，奥浦迈（688293）下跌6.39%。消息面上，2026Q3创新药在医药板块内持仓占比降至43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202611063924769861.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202611063924769861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["159938","BK1574","BK1515","IBBQ","LNGR","06978","09939","MEDX","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681966079","title":"礼邦医药-B(09637)11月5日斥资约11.54万港元回购6600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681966079","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681966079?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:03","pubTimestamp":1793887391,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B(09637)发布公告，于2026年11月5日该公司斥资约11.54万港元回购6600股，回购价格为每股17.29至17.64港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","BK1191","BK1574","09637","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681602935","title":"东方证券股份有限公司(DFZQ)增持劲方医药-B(02595.HK)29.96万股 每股作价约23.44港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681602935","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681602935?lang=zh_cn&edition=full","pubTime":"2026-11-05 19:25","pubTimestamp":1793877919,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","02595","BK1515","BK1161","BK1147","BK1564","BK1574","03958"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681047519","title":"电子医药双热！私募10月调研图谱出炉：高毅、淡水泉、聚鸣频频现身，源杰科技、胜宏科技最受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2681047519","media":"私募一线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681047519?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:24","pubTimestamp":1793870640,"startTime":"0","endTime":"0","summary":"近期，A股私募调研活跃度持续上行。整体来看，电子和医药生物成为最受关注的两大板块，百亿私募与中小私募均在加大调研投入力度。当月共有130家私募调研次数不少于10次，其中前十名机构的调研次数均超过50次。在百亿私募阵营中，除高毅资产外，淡水泉和聚鸣投资也跻身机构调研次数前十，分别调研63次和54次。此外，还有9家百亿私募当月调研次数在20次及以上，包括上海常春藤私募、姚泾河私募、重阳投资、景林资产等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/original/2026-11-05/doc-inixsrry6074350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0164865239.USD","BK0197","LU0039217434.USD","LU1979443071.USD","BK1574","SGXZ49509284.SGD","BK1515","SGXZ81163826.USD","LU0531971595.HKD","LU0164880469.USD","159938","LU0871576103.HKD","LU1481107354.HKD","BK0214","BK1170","02476","09939","BK1161","LU1934453819.USD","LU0469268626.HKD","LU0149721374.USD","300476","LU1808992512.USD","688498"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681442510","title":"11月5日山外山涨5.21%，圆信永丰医药健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681442510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681442510?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:55","pubTimestamp":1793868914,"startTime":"0","endTime":"0","summary":"证券之星消息，11月5日山外山涨5.21%，收盘报10.9元，换手率3.37%，成交量15.07万手，成交额1.63亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为圆信永丰基金的圆信永丰医药健康A。圆信永丰医药健康A目前规模为2.82亿元，最新净值1.8553，较上一交易日上涨1.54%，近一年下跌5.89%。圆信永丰医药健康A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500029609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","BK0251","688410","BK1574","150219","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681049058","title":"迪哲医药(688192.SH)：血液瘤产品多项研究成果入选第68届美国血液学会(ASH)年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2681049058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681049058?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:17","pubTimestamp":1793866675,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 发布公告，公司将于12月12日至15日在美国新奥尔良举办的第68届美国血液学会年会上，公布血液肿瘤管线的8项最新临床研究成果，包含3项口头报告和5项壁报展示，涉及公司血液瘤领域的三大核心产品——高选择性JAK1抑制剂高瑞哲、LYN/BTK双靶点抑制剂比瑞替尼以及新一代EZH1/2双靶点小分子抑制剂GW5282。此次大会上高瑞哲共有5项最新临床研究进展入选。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","LU2463526074.USD","BK1515","688192","159938","BK0239","BK1161","ASH","BK4109","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681142100","title":"医药股午后继续走高 中国生物制药涨超7%百济神州涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681142100","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681142100?lang=zh_cn&edition=full","pubTime":"2026-11-05 13:48","pubTimestamp":1793857680,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端医药股午后继续走高，创新药、CRO概念领衔。截至发稿，中国生物制药（01177）上7.18%，报5.52港元；百济神州（06160）上涨6.13%，报245.80港元；康方生物（09926）上涨4.85%，报86.50港元；信达生物（01801）上涨3.65%，报88.15港元；科伦博泰生物（06990）上涨2.89%，报455.20港元；药明康德（02359）上涨1.72%，报201.20港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-11-05/doc-inixsfae6194220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","159938","LU2328871848.SGD","KURE","BK1574","LU0307460666.USD","IE00BZ08YS42.EUR","BK0239","BK1515","BK1588","LU1251922891.USD","BK1500","IE00BZ08YR35.GBP","BK4139","06160","ONC","IE00BZ08YT58.USD","BK4526","BK4588","HK0000165453.HKD","BK1161","BK1191","LU0588546209.SGD","LU1969619763.USD","BK4585","LU0228659784.USD","01177","BK1583","LU1303224171.USD","BK1521","688235","LU0828237510.HKD","LU1719994722.HKD","LU1770034418.SGD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681015969","title":"港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2681015969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681015969?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:47","pubTimestamp":1793846861,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，医药股今早继续走高，创新药、CRO概念领衔。中国生物制药11月4日盘后公告，与跨国药企勃林格殷格翰就下一代肿瘤疗法达成重磅对外授权，覆盖6个创新药临床前项目。公司可获3.58亿美元首付款，潜在总额最高达70亿美元，刷新公司BD交易金额纪录。东方证券指出，从医药整体来看，2026年前三季度营收同比增长1.4%，归母净利润同比增长11.6%，扣非归母净利润同比增长18.3%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0244354667.USD","BK4585","LU1719994722.HKD","KURE","01177","BK1161","BK4588","LU0607220059.USD","LU2097828631.EUR","BK1589","LU0326950275.SGD","BK1583","LU0650527681.SGD","LU1831875114.USD","159938","LU0463099449.HKD","BK1500","LU1251922891.USD","LU0228659784.USD","LU2488822045.USD","LU2097828714.EUR","LU1969619763.USD","LU2242644610.SGD","LU0594300179.USD","BK1515","LU2097828805.USD","LU2097828557.USD","01801","LU2328871848.SGD","LU2097828474.EUR","BK1574","01477","LU0149534421.HKD","LU1770034418.SGD","BK1588","VXUS","BK1521","LU1188198961.HKD","LU0828237510.HKD","06990","HK0000165453.HKD","BK1191","06160","IE00BZ08YR35.GBP","09939","IE00BZ08YT58.USD","KCAI","LU0588546209.SGD","LU0196878994.USD","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681097518","title":"迪哲医药（688192）11月4日主力资金净卖出403.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681097518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681097518?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:32","pubTimestamp":1793838728,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月4日收盘，迪哲医药报收于64.1元，上涨8.35%，换手率2.0%，成交量9.24万手，成交额5.7亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入6455.94万元，融资偿还3643.29万元，融资净买入2812.65万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500009906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09939","BK1574","BK1161","688192","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681929069","title":"股市必读：大参林新发布《大参林医药集团股份有限公司关于控股股东股份解除质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681929069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681929069?lang=zh_cn&edition=full","pubTime":"2026-11-05 01:57","pubTimestamp":1793815069,"startTime":"0","endTime":"0","summary":"公司公告汇总大参林医药集团股份有限公司关于控股股东股份解除质押的公告大参林医药集团股份有限公司于2026年11月4日发布公告，控股股东之一柯康保先生将其持有的25,500,000股公司股份解除质押，解除质押股份占其持股总数的14.31%，占公司总股本的2.16%。截至公告日，公司控股股东及其一致行动人合计持有公司股份706,668,982股，占公司总股本的59.87%，累计质押股份53,072,320股，占其所持股份比例7.51%，占公司总股本比例4.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500003640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1515","BK0185","BK1161","BK0114","159938","BK0209","603233","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680026052","title":"礼邦医药-B(09637.HK)11月4日耗资约124.85万港元回购7.41万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680026052","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680026052?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:01","pubTimestamp":1793800916,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","09637","09939","BK1191","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680605653","title":"新股消息 | 和美医药(00054.HK)暂缓港股上市 将于11月9日开始退款","url":"https://stock-news.laohu8.com/highlight/detail?id=2680605653","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680605653?lang=zh_cn&edition=full","pubTime":"2026-11-04 20:05","pubTimestamp":1793793905,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00054","BK1515","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680903064","title":"汇添富基金增持劲方医药-B(02595)29.96万股 每股作价约23.44港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680903064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680903064?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:19","pubTimestamp":1793791162,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月30日，汇添富基金增持劲方医药-B(02595)29.96万股，每股作价23.4445港元，总金额约为702.40万港元。增持后最新持股数目为1777.48万股，持股比例为5.05%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","09939","BK1574","BK1161","159938","BK1515","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680488036","title":"11月4日键凯科技涨6.30%，圆信永丰医药健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680488036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680488036?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:16","pubTimestamp":1793783802,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日键凯科技涨6.30%，收盘报76.72元，换手率6.07%，成交量3.68万手，成交额2.73亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为圆信永丰基金的圆信永丰医药健康A。圆信永丰医药健康A目前规模为2.82亿元，最新净值1.8272，较上一交易日下跌1.82%，近一年下跌8.52%。圆信永丰医药健康A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["150219","BK1515","BK1574","BK1161","688356","09939","BK0229","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680036375","title":"迪哲医药涨8.35%，东海证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680036375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680036375?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:10","pubTimestamp":1793783456,"startTime":"0","endTime":"0","summary":"今日迪哲医药涨8.35%，收盘报64.1元。研报中预计公司2026-2028年实现归母净利润分别为-4.48/0.78/4.81亿元。公司研发快速推进，国际化价值兑现，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为67.43%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中金公司的张琎。迪哲医药个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","161027","159938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.0222},{"period":"1month","weight":-0.2069},{"period":"3month","weight":-0.2376},{"period":"6month","weight":-0.5274},{"period":"1year","weight":-0.2247},{"period":"ytd","weight":-0.2959}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.333333,"avgChangeRate":0.058562},{"month":4,"riseRate":0.666667,"avgChangeRate":0.374359},{"month":5,"riseRate":0.5,"avgChangeRate":0.006013},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.081543},{"month":7,"riseRate":0.571429,"avgChangeRate":0.098094},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.060443},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.106422},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.121773},{"month":11,"riseRate":0.714286,"avgChangeRate":0.066196},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}